Chosa ApS
Private limited companyCVR 43134477København VActive
Chosa ApS is a private limited company, based in København V, active in manufacture of pharmaceutical preparations, founded in 2022. The company made a loss in both 2024 and 2025, most recently DKK 2.6m. Equity fell to DKK 5.2m in 2025.
Key figures · financial year 2025
What has changed
calculated from recorded figures and datesFinancials: 2025 against 2024
- The loss got smaller: from DKK 3.6m to DKK 2.6m (2024 → 2025).
- Equity fell 31% (2024 → 2025), to DKK 5.2m.
Employees
- 4 more employees than a year earlier: 8 (07/2026) against 4 (07/2025).
Management and owners, last 24 months
- Stepped down: Neil Goldsmith (director, 25/11/2025).
Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.
Financial statements
Financial years 2022–2025 · amounts in DKK thousandEquity and net profit
| 2022 | 2023 | 2024 | 2025 | Change | |
|---|---|---|---|---|---|
| Revenue | not stated | not stated | not stated | not stated | – |
| Gross profit | −467 | −1,543 | −1,131 | −2,136 | −88.9% |
| Operating profit (EBIT) | −817 | −2,043 | −2,373 | −3,347 | −41% |
| Profit before tax | −817 | −1,967 | −2,310 | −3,326 | −44% |
| Net profit | −715 | −2,070 | −3,587 | −2,632 | +26.6% |
| Total assets | 7,949 | 10,295 | 11,189 | 13,427 | +20% |
| Equity | 7,761 | 8,991 | 7,485 | 5,175 | −30.9% |
| Liabilities | 188 | 1,304 | 3,705 | 8,252 | +122.7% |
| Cash and cash equivalents | 645 | 518 | 0 | 953 | – |
| Average number of employees | 0 | 0 | 1 | 0 | −100% |
Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report. Revenue is not stated for 2022, 2023, 2024, 2025: smaller companies may omit it, and we do not derive it from other figures.
Download the figures as CSV · free with an account, amounts in whole DKK
Signals from the financial statements
calculated from the 2025 figuresLoss for 4 years in a row
Net result has been negative in 2022–2025.
How is this calculated?
Net result is negative in the two or more latest annual reports in a row.
Equity fell sharply
Equity fell 31% from 2024 to 2025 (DKK 7.5m to DKK 5.2m).
How is this calculated?
Equity has fallen by at least 30% from the previous annual report, and it was positive the year before.
The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.
Annual reports
4 financial years| Financial year | Period | Published | Figures for | Documents |
|---|---|---|---|---|
| 2025 | 01/01/2025 – 31/12/2025 | 20/04/2026 | The company | PDF not statedXBRL |
| 2024 | 01/01/2024 – 31/12/2024 | 23/07/2025 | The company | PDFXBRL |
| 2023 | 01/01/2023 – 31/12/2023 | 10/07/2024 | The company | PDFXBRL |
| 2022 | 18/03/2022 – 31/12/2022 | 22/03/2023 | The company | PDFXBRL |
The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.
Employees
monthly figures from CVRPosition in the industry
59 companies in the databaseComparison with the other companies in manufacture of pharmaceutical preparations based on the latest financial year.
Industry median: gross profit DKK 2.8m, net profit −DKK 2.2m, equity DKK 5.2m, 10 employees.
Compared with similar companies
size, age and company form| Group | Gross profit | Equity |
|---|---|---|
| Companies with fewer than 20 employees69,967 companies in the comparison | No. 69,219of 69,742 Better than 1% | No. 13,840of 69,964 Better than 80% |
| Same industry and fewer than 20 employees37 companies in the comparison | No. 24of 36 Better than 34% | No. 12of 37 Better than 69% |
| Companies that are founded within the last five years16,662 companies in the comparison | No. 16,436of 16,614 Better than 1% | No. 1,287of 16,661 Better than 92% |
| All companies of type ApS66,508 companies in the comparison | No. 65,953of 66,379 Better than 1% | No. 10,979of 66,505 Better than 83% |
The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.
Compare with the industry
Manufacture of pharmaceutical preparations- Chosa ApS−DKK 2.1m
- Novo Nordisk A/SDKK 250.3bn
- H. Lundbeck A/SDKK 20.4bn
- Chosa ApS−DKK 2.6m
- Novo Nordisk A/SDKK 102.4bn
- H. Lundbeck A/SDKK 3.2bn
- Chosa ApSDKK 5.2m
- Novo Nordisk A/SDKK 194bn
- H. Lundbeck A/SDKK 24.9bn
- Chosa ApS8
- Novo Nordisk A/S27,279
- H. Lundbeck A/S2,261
Latest financial year per company. Choose up to three companies from the largest in the industry.
Owners and group
from the Public Ownership Register- Chosa Oncology AB100%
Management
2 active registrationsExecutive management
| Name | Role | Appointed |
|---|---|---|
| Peter Buhl | CEO | 18/03/2022 |
| Claus Frisenberg Pedersen | Director | 06/05/2022 |
- Founders
- Buhl Krone Holding ApS, Lh|lh Invest ApS, Arrow Strategy Holding 2 ApS, Arrow Invest 1 ApS, IPO Nordic Fund A/S, SH Verwaltungsgesellschaft mbH
Former management (1)
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| Neil Goldsmith | Director | 06/05/2022 | 25/11/2025 |
Signing rule: Selskabet tegnes af den samlede direktion, eller af to direktører i forening.
Address and production units
1 active production unitsPuggaardsgade 17
1573 København V
| Production unit | Address | Employees | P number |
|---|---|---|---|
| Chosa ApS | Puggaardsgade 17, 2. tv, 1573 København V | 6 | 1028094775 |
Purpose
Virksomhedens formål er at udvikle og erhvervsmæssigt udnytte kræftbekæmpende behandlinger og andre aktiviteter, som kan forbindes med kræftbekæmpende behandlinger samt hermed beslægtet virksomhed.
The purpose is quoted from the register in Danish.
Changes year by year
36 registered events20261 changeaccounts 1
- AccountsAnnual report for 2025 published
20252 changesmanagement 1 · accounts 1
- ManagementNeil Goldsmith stepped down as director
- AccountsAnnual report for 2024 published
20242 changesaddress 1 · accounts 1
- AddressMoved to Puggaardsgade 17, 2. tv, 1573 København V
- AccountsAnnual report for 2023 published
202313 changesaddress 1 · accounts 1 · ownership 10 · capital 1
- AddressMoved to Deventergade 4, 2791 Dragør
- AccountsAnnual report for 2022 published
- OwnershipChosa Oncology AB registered as owner (100%)
- OwnershipIPO Nordic Fund A/S is no longer registered as owner
- Ownership1632 LLP is no longer registered as owner
- OwnershipSmerud Medical Research International AS is no longer registered as owner
- OwnershipArrow Strategy Holding 2 ApS is no longer registered as owner
- OwnershipBUHL KRONE HOLDING ApS is no longer registered as owner
- CapitalShare capital changed from 8,475,500 DKK to 9,873,960 DKK
- OwnershipIPO Nordic Fund A/S registered as owner (10%)
- OwnershipLH|LH INVEST ApS is no longer registered as owner
- OwnershipSH Verwaltungsgesellschaft mbH is no longer registered as owner
- OwnershipIPO Nordic Fund A/S is no longer registered as owner
202218 changescapital 1 · ownership 13 · management 3 · founded 1
- CapitalShare capital changed from 7,475,500 DKK to 8,475,500 DKK
- OwnershipIPO Nordic Fund A/S registered as owner (5%)
- OwnershipLH|LH INVEST ApS registered as owner (5%)
- Ownership1632 LLP registered as owner (5%)
- OwnershipSH Verwaltungsgesellschaft mbH registered as owner (5%)
- OwnershipSmerud Medical Research International AS registered as owner (10%)
- OwnershipLH|LH INVEST ApS is no longer registered as owner
- OwnershipIPO Nordic Fund A/S is no longer registered as owner
- OwnershipSH Verwaltungsgesellschaft mbH is no longer registered as owner
- ManagementNeil Goldsmith appointed director
- ManagementClaus Frisenberg Pedersen appointed director
- FoundedRegistered as Chosa ApS
- ManagementPeter Buhl appointed ceo
- OwnershipLH|LH INVEST ApS registered as owner (10%)
- OwnershipIPO Nordic Fund A/S registered as owner (15%)
- OwnershipSH Verwaltungsgesellschaft mbH registered as owner (10%)
- OwnershipArrow Strategy Holding 2 ApS registered as owner (15%)
- OwnershipBUHL KRONE HOLDING ApS registered as owner (33.33%)
Related companies
Same industry in København
- H. Lundbeck A/S2,261 employees
- AJ Vaccines A/S499 employees
- Tetra Pharm Technologies ApS39 employees
- Motilitycount ApS29 employees
- Freya Biosciences ApS18 employees
- Zerion Pharma A/S15 employees
Same people in management
- Finn L. & Davidsen A/Svia Claus Frisenberg Pedersen
- Nellemann A/Svia Claus Frisenberg Pedersen
- Sjeb A/Svia Claus Frisenberg Pedersen
- Unibio A/Svia Neil Goldsmith
- Symbion A/Svia Peter Buhl
- Nellemann Holding A/Svia Claus Frisenberg Pedersen
Largest in the industry
- Novo Nordisk A/SDKK 250.3bn
- H. Lundbeck A/SDKK 20.4bn
- Leo Pharma A/SDKK 8.2bn
- Alk-abelló A/SDKK 4.2bn
- Bavarian Nordic A/SDKK 3bn
- Pharmacosmos A/SDKK 1.6bn
Source and updates
The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026. The company is protected against advertising; contact details are not shown, and the data must not be used for marketing.